SPHS Possible Breakout?
SPHS has been testing it's resistance points higher and higher over the past few months after the sudden gap-down in mid-December of last year. Sophiris Bio Inc., a bio-pharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, has shown a recent development of their PRX302 treatment and doctors say it could serve as a viable resource by targeting and destroying cancer ridden prostate tissue. This can only mean more money flowing into the company's pockets. I believe by the company's progress and the stocks movement in the market we could see this stock breaking it's resistance and spiking up to around 1.20-1.60 in the coming weeks.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.